'Anyone who tries to develop new drugs for diseases of the nervous system is looking for a good way of going out of business.' Leo Hollister, 1962 Never before has the promise for therapeutic breakthroughs in psychiatry been greater. An explosion of knowledge in basic neurobiology, resulting in ever-increasing discoveries of new neurotransmitters and receptors, has generated the necessary momentum for psychopharmacology to apply its new information towards the development of novel and improved treatments for diseases of the nervous system. In order to capitalize upon the opportunities at hand, it is important to consider not only the basic needs of patients with mental disorders, but also the strategy by which the fruits ofthe basic science laboratories can best be brought to the bedside. Are drugs, in fact, at all necessary for the treatment of mental illness, and if so, where and how could innovations occur in psychopharmacology? Should new uses be found for old drugs or should entirely new chemical entities be developed? Furthermore, how can the full potential of any drug be best exploited (e.g. new technology)? With these questions in mind, this paper examines the status of current drug therapies in the major nervous system diseases, and attempts to foresee the direction future research could take in each of these areas. Finally, a 'wish list' is proposed for new drug development in the 21st century.
Are drugs necessary?
The problems drugs cause when abused by members of the general population, or when inappropriately prescribed by physicians, has given rise to the accusation that we are an 'overmedicated society". It has been suggested that alternatives to drug therapy should be sought, especially in the case of mental illnesses where this 'overmedication' is most likely to occur. One alternative to drug therapy could take the fonn of 'prescriptive' psychotherapies, where the needs of an individual would be matched to a variety of psychotherapy techniques rather than the current practice of having a single therapy which is applied to several psychological problems. Great strides are already being made in this area. Rather than using a technique such as family therapy for everything from anxiety to schizophrenia, a standardized psychotherapy, such as brief interpersonal therapy2 or cognitive therapy' is prescribed for individuals meeting specific selection criteria. Often, however, these techniques will not be potent enough or rapid enough to be truly beneficial to a patient, in which case drugs could be co-prescribed. The treatment of patients with mental illnesses may eventually be approached in the same manner that physicians now treat hypertension. Each patient's therapy could be individualized, based on a close examination oftheir lifestyle, habits, medical health, medical history, environmental influences and physical exercise. Thus, the solution appears not to be to see the issue as a question of drugs as opposed to other approaches, but rather to see drugs as possibly playing only a part in an all-encompassing therapy. If there is to be a place for drugs in mental illness, what type of drugs are needed? Ideally, we would have the ability to produce drugs that would simply prevent or cure mental illness. Whether this will ever be achieved for some illnesses is questionable, but definite advances are being made in this direction (for example, the monoamine oxidase B inhibitors, such as pargyline and deprenyl, have been proposed as prophylactic agents which may actually prevent the development of Parkinson's disease4). More realistically, drug development could have as its minimum requirement two goals: new drugs should (1) reduce disease symptoms and (2) have fewer or less problematic side effects when compared with existing drugs on the market.
Dressing-up 'old' drugs Given that drugs are sometimes necessary, how does one go about producing better and more effective ones? Already there are many drugs available; is it possible that we have not yet learned how to tap into all their resources? With a bit of imagination and innovation, these 'old' drugs could become improvements to existing therapies. Various approaches are available for altering these drugs, as can be seen in Table 1 . Although there is little incentive for the pharmaceutical industry to lead in this area, a number of academic investigators have successfully exploited at least one variation of this approach, namely in applying an 'old' drug to a different disease entity such as in the case of carbamezepine for mania5, clonidine for Tourette syndrome6 and phenelzine for panic disorder7. Practising clinicians have long been silently innovating with old chemical entities in another manner as well, namely they have been individualizing pharmacotherapy. The problems of 'real' patients often fail to fit neatly into diagnostic categories, so that one patient's depression and another patient's anxiety may both respond optimally to an antidepressant. An extension ofthis approach has been to redefine a mental disorder as that syndrome which improves after a drug is given.
A third way to innovate with old chemical entities is to use them as a starting point from which structural modifications can be made to improve the parent drug. This approach is one of the most aggressively pursued by the pharmaceutical industry, and has resulted in a rich array of tricyclic antidepressants and benzodiazepines. However, this approach can be over-pursued and be ultimately unproductive, saturating the field with 'me-too' products and 'fine tune' variations on a single theme, resulting in minor side effect improvements but not in any significant therapeutic breakthroughs.
Innovating with new chemical entities Certainly, the greatest hope for a new therapeutic breakthrough comes from compounds yet to be invented. The development of a completely new drug can be approached in at least three ways (Table  2) : first, by pathophysiologic means, in which the biochemical lesion causing a mental disease is located and the therapy is correspondingly developed from this knowledge; secondly, by biologically empiric means, whereby new drugs which target specific enzymes or receptors are developed by exploiting rational structure-activity relationships or by natural product screening; and thirdly, by serendipity.
The pathophysiologic approach to new drug invention has perhaps been most successfully implemented in the example of Parkinson's disease8, where a biochemical lesion was first discovered (dopamine deficiency), and this led to the rational development of precursor replacement therapy (levodopa). Unfortunately, most CNS disorders have no known causative biochemical lesion which can serve as a target for correcting with new drug therapies. The pathophysiologic approach to new drug innovation is vitally dependent upon ongoing research which has as its aim the discovery of biochemical aetiologies of mental disorders.
The biologically empiric approach is the area where the greatest effort is likely to be focused in the next decade. That is, the plethora of new enzymes, receptors and neurotransmitters found in the brain9'0 has generated dozens of targets for the medicinal chemist, and it is likely that a large number of potent, selective enzyme inhibitors and neurotransmitter receptor agonists and antagonists will become available for clinical testing in the near future. These new chemical entities will flow either from knowledge of the molecular characteristics of the target receptors, or from natural and synthetic product screening (or from serendipity). Once selected for human testing, however, it will be difficult to predict, with certainty, the appropriate CNS disorder which will become the therapeutic target for these new drugs, since we still lack much knowledge about the molecular basis of most CNS disorders. Thus, new chemical entities may increasingly be employed as tools to understand pathophysiology prior to implementing these tools as therapies. In this approach, a new receptor antagonist, for example, may be administered to half a dozen different CNS syndromes, so as to observe behavioural effects consequent to receptor blockade. The results of such a study could then be used to predict disorders Although the disease selected for study might not be the ultimate disorder which will be matched to a therapeutic application of the new drug, the biologically empiric approach requires that this clinical testing be conducted in a hypothesis-oriented atmosphere (not random screening) so that potential therapeutic application will have the maximum chance of being recognized. Serendipity will hopefully favour the prepared mind, and provide unexpected bonuses as well.
New technologies
Another area of research has not focused on drugs but rather on the technology surrounding them. Neuroimaging aids the scientist in 'seeing' what a drug does once in the body, while drug delivery systems are allowing for more sophistication in the administration of drugs.
Neuroimaging: Dramatic advances are being made in noninvasive neurodiagnostic techniques which can image the living human brain. These new neuroimaging technologies are beginning to allow us to visualize not only the structure but also the function of the brain. The mathematic methodology of computerized tomography can now be applied to traditional X-ray (computerized tomographic or CT scans) and to magnetic signals (nuclear magnetic resonance or NMR)"1 as well as to isotopes emitting radioactivity (positron emission tomography or PET)'2. These developments enable investigators to label neurotransmitters and their receptors with new drugs which will eventually allow them to document the selective targeting of drugs to specific sites in a 1 3 disease Drug delivery systems: Another area of technical development relevant to the CNS is that of drug delivery. One of the biggest problems confronting drug therapy of CNS disorders is the ability to get the relevant drug to the place of interest at the rates and time required'4. Thus, the integration of various drug delivery systems (for example transdermal patches and osmotic pumps'5) with new chemical entities should be particularly relevant to the development of CNS drugs'6. In the future, it is possible that some CNS disorders will be treated by pumps worn externally, or implanted under the skin, which deliver the drug subcutaneously, intravenously, or even directly into the brain.
An even more novel approach to the drug delivery problem is the use of brain transplants. In adult rats, grafts of fetal substantia nigra implanted in the lateral ventricle have been shown to make functional connections to the caudate nucleus'7. In patients with Parkinson's disease, autografts of adrenal medulla into the caudate nucleus have also been performed. In the near future, it may become possible to develop patented cell lines, using recombinant DNA techniques, which would 'teach' cells to make the neurotransmitter of interest and then to transplant these cell lines into the brain sites of diseases. Yet another area of interest in this field is the development of implantable semiconductors or pacemakers which could be placed into the desired brain site.
Psychopharmacologist's 'wish list' 21st century How will the current explosion ofall these laboratory discoveries translate into significant advances at the bedside? What disorders are poised as appropriate targets for the drug innovation strategies suggested above? Finally, which areas are most likely to bear fruit in this century? Engaging in a bit of wishful thinking together with neuroscience speculation, it appears that advances may first occur for CNS disorders which already have some form of current treatment, whereas any major breakthroughs may only appear early in the 21st century (Table 3) . Table 3 . Psychopharmacologist's 'wish list'
(1) Agents to enhance cognitive failure (2) Rapid-acting, safer, more effective antidepressant (3) Non-neuroleptic antipsychotic (4) Non-addicting analgesic (5) Non-sedating, non-addicting anxiolytic (6) Prevent neuronal death or restore neuronal integrity:
prophylaxis, transplants, programmed regeneration, blocking exogenous and endogenous neurotoxins Depression, mania and affective disorders Major affective disorders have a variety of powerful agents available for treatment today. The heterocyclic amine-reuptake blocking antidepressants are the hallmark of current therapy, although there are other effective treatments which include the monoamine oxidase inhibitors, lithium and electroconvulsive therapy. The goals of future research should be to develop more rapidly acting agents which are effective in a larger percentage ofpatients and which are safer than the currently marketed drugs. Since the mode of action of the heterocyclics, the monoamine oxidase inhibitors and ECT may be to cause down-regulation of certain neurotransmitter receptors (in particular beta-1-adrenergic and serotonin-2 receptors)'8, it seems logical that novel therapeutic agents which can down-regulate receptors more rapidly and more specifically than the heterocyclics should be candidates as new antidepressants.
Schizophrenia
The introduction of the dopamine receptor blocking neuroleptics in the 1950s revolutionized the treatment of schizophrenia by effectively controlling the 'positive symptoms' of this disorder, such as delusions and hallucinations, in many patients. However, there are still some patients who are not effectively treated by these agents and, moreover, for those who are responders, there is always the risk of developing tardive dyskinesia. Furthermore, since neuroleptics treat predominantly the 'positive symptoms' of the disorder, the patient is by no means 'cured'. In fact, the most disabling untreatable elements ofthe schizophrenic syndrome today are the 'negative symptoms' described as the Kraepelinian decline in cognitive functioning, also known as 'the dementia of dementia praecox"'9. This cognitive loss is characterized by apathy, alogia, abulia, social withdrawal and affective blunting. Since these negative symptoms are largely unaffected by neuroleptics, it is conceivable that they are not as closely related to hyperactive dopaminergic functioning as postulated for the positive symptoms20. Future research into the treatment of schizophrenia should develop a neuroleptic which deals more effectively with the positive symptoms of the disorder and which would be devoid of chronic side effects such as tardive diskinesia21. This type of neuroleptic would probably still be ineffective in treating the negative s-ymptoms of the disorder and thus research in this area should focus on another mechanism of action which is likely to treat this cognitive loss. Presently, there is no existing treatment for the negative symptoms of schizophrenia, but it has been suggested that serotonin may be involved since fenfluramine appears to improve negative symptomatology in adult schizophrenics22, and to enhance cognitive functioning in autistic children23. Yet another area of research could look at the neuropeptides such as cholecystokinin or neurotensin which may also be involved in these negative symptoms21.
Anxiety, phobia, panic and obsessive-compulsive disorder The benzodiazepines are the therapeutic class of agent which have become the standard of care for many of these disorders. Unfortunately the benzodiazepines have strong sedative actions and also have some abuse and addiction potential, possibly due to the fact that benzodiazepines are 'full' agonists at the benzodiazepine receptor. Thus, it is possible that 'partial' agonists would not be as powerful as the currently marketed full agonists and therefore might be less sedating and addictive. Also, several new compounds which share actions on 5HTL4 receptors in the buspirone-gepisone-ipsapirone series are interesting candidates for novel anxiolytics24.
Pain
In addition to classic opioids, serotonin-blocking antidepressant compounds, such as amitriptyline, have some efficacy in treating chronic pain and in migraine prophylaxis25. Could other serotonergic compounds, acting on serotonin receptor subtypes, also be effective analgesics? Since the addictive properties of most of the 'old' narcotic drugs pose serious problems, it is possible that these undesirable properties of opiates might be reduced if their drug delivery system was altered. For example, the transdermal delivery of high-potency analgesics such as fentanyl could allow for very low, continuous doses which may prove to be useful. Finally, it has been shown that neurotransmitter substance P has an important role in the pain pathway26. More research needs to be done to see if substance P antagonists would be potential non-addicting analgesics when delivered to the necessary site of action.
Movement disorders
The treatment of Parkinson's disease with levodopa is one ofthe success stories of neuropharmacology in the 20th century. However, dopaminergic agents do not halt the progression of this disorder and are thus merely palliative. Furthermore, chronic replacement therapy has its own problems, namely, the development of the 'wearing off', 'end of dose', and 'on-off' effects. New drug delivery devices, such as transdermal delivery ofa dopamine agonist, may supply a constant rate of drug to the caudate and level out the swings in Parkinson's disease patients"6.
The movement disorders in most need of treatment are those which result from dead or degenerating neurones (e.g. stroke, spasticity, multiple sclerosis, etc). Replacing the lost functions of these neurones will require identification of the neurotransmitter and receptors utilized by the malfunctioning pathways. These are disorders where brain transplants may play a significant role. The development ofa centrally active glycine agonist has theoretical appeal for certain forms of spinal rigidity caused by trauma, stroke or in certain degenerative conditions such as the stiff man syndrome. This may also become an effective treatment for strychnine and tetanus poisonings. If neurodegenerative disorders are caused in some instances by excessive stimulation of glutamic acid receptors, glutamate antagonists might open up entirely new therapeutic possibilities for stroke, motor neuron disease, and Alzheimer's disease27.
Cognitive disorders
These are human disorders of 'higher functioning' and include Alzheimer dementia, alcoholic dementia, Huntington dementia, the dementia of dementia praecox (schizophrenia), learning disabilities of children, attention deficit disorders, mental retardation and infantile autism, amongst others. Demographic statistics suggest that this group of disorders causes much suffering in large numbers of people at very great human and financial cost to society. Initially drugs will be needed which can aid the victim or which can arrest further progression of the deterioration. Since it is still not clear which neurotransmitters and which areas of the brain are affected, neuroimaging techniques may be quite useful in gaining an understanding ofthese disorders. In the absence ofany current effective therapy, it can be argued that developing treatments for these disorders would be among the highest priorities of any CNS programme in the future.
Conclusion
The pharmacological tools that have been successful in the past for treating the problems of the nervous system include neurotransmitter replacement therapies, receptor agonist and antagonist therapies, and enzyme inhibitor therapies. Whether these approaches will bear fruit in the development of significant new treatments of CNS disorders in the future remains to be seen. Unfortunately, we often do not know which neurotransmitter to replace, which receptor to turn on or off, or which enzyme to inhibit. Thus, advances in the therapy of CNS disorders rests in part upon advances in the understanding of the aetiology and pathophysiology of the target disorders. However, this should not be too discouraging because there are several strategies for new drug innovation and also because the best therapies of CNS disorders available today were discovered largely by empiricism, serendipity and plain hard work. The future for the development of new drugs for mental diseases has never looked brighter.
